Search Results
Your search for Staff matches 7032 pages
Showing 2901 - 2950Penn Medicine Appoints Robert Vonderheide, MD, DPhil, to Second 5-Year Term as Director of Abramson Cancer Center
Robert H. Vonderheide, MD, DPhil, has been appointed to a second 5-year term as Director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 U.S. Food and Drug Administration approvals in oncology for therapies based on studies...
David Braun, MD, PhD, Joins Prostate and Urologic Cancers Program at Yale Cancer Center
Yale Cancer Center and Smilow Cancer Hospital welcome David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology) and a member of the Center for Molecular and Cellular Oncology (CMCO). Dr. Braun cares for patients with kidney cancer. Dr. Braun received his PhD in Computational Biology ...
Sam Mbulaiteye, MBChB, MPhil, MMed, Named 2022 Scientist of the Year by Lymphoma Foundation of America
Sam Mbulaiteye, MBChB, MPhil, MMed, senior investigator in the Infections and Immunoepidemiology Branch, in the Division of Cancer Epidemiology & Genetics of the National Cancer Institute, was recently recognized by the Lymphoma Foundation of America with its 2022 Scientist of the Year Award....
J. Paul Taylor, MD, PhD, Named Scientific Director and Executive Vice President of St. Jude
J. Paul Taylor, MD, PhD, has been named Scientific Director and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Taylor steps into the role during a pivotal time of growth for the hospital. Under its $11.5 billion, 6-year strategic plan, the institution’s scientific...
AACR Honors Lee Ellis, MD, for Contributions to Education and Training in Cancer Research
The American Association for Cancer Research (AACR) has named Lee Ellis, MD, Professor of Colon and Rectal Surgery at The University of Texas MD Anderson Cancer Center, Houston, as the 2022 recipient of the AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in...
FDA Approvals in Hematologic Oncology 2021–2022
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in hematologic oncology. Axicabtagene Ciloleucel: On April 1, 2022, axicabtagene ciloleucel (Yescarta) was approved for adult patients with...
Expert Point of View: Laurie H. Sehn, MD, MPH
The moderator of the session, Laurie H. Sehn, MD, MPH, Clinical Professor at the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, called the results of the TRANSFORM trial “quite remarkable” and said chimeric antigen receptor (CAR) T-cell therapy has the...
TRANSFORM: Lisocabtagene Maraleucel Improves Outcomes in Relapsed or Refractory Large B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel could prove to be the new standard-of-care treatment for patients with relapsed or refractory large B-cell lymphoma in the second-line setting, according to data presented at the 2021 American Society of Hematology (ASH)...
Can AI Assist in Predicting Spinal Fractures in Patients With Cancer?
A new study published by Ahmadian et al in the International Journal for Numerical Methods in Biomedical Engineering suggests how scientists may use artificial intelligence (AI) to predict how cancer may affect the probability of fractures along the spinal column. The report described how the...
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer
On May 4, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. According to the approval, patients had to have received a prior anti-HER2–based regimen either in the...
Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research
Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, discusses the battle against treatment resistance and how to overcome it, as well as the power of observational clinical data in precision oncology, derived largely from his experience with Project GENIE, and the role of genetic...
Study Examines Link Between Emphysema and Lung Cancer Risk
Computed tomography (CT)-detected emphysema may be linked to a higher risk of lung cancer, a risk that increases with emphysema severity, according to a new study published by Yang et al in the journal Radiology. Lung cancer is the primary cause of cancer-related death worldwide. However, lung...
Study Reports New Potential Target for CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has made an impact on the treatment of certain blood cancers, but in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor targets not expressed in vital tissues. In a new study ...
Do AYA Cancer Survivors Face a Higher Risk of Developing and Dying From a New Primary Cancer?
New findings published by Hyuna Sung, PhD, and colleagues in the Journal of the National Cancer Institute showed that 5-year survivors of adolescent and young adult (AYA) cancer in the United States have a higher risk of developing—and nearly double the risk of dying from—a new primary cancer,...
Research Suggests Over Half of Eligible Women Would Prefer Self-Sampling for Cervical Screening
According to the results of a new study published by Drysdale et al in the Journal of Medical Screening, 51.4% of women preferred self-sampling for human papillomavirus (HPV)-based cervical cancer screening, compared to 36.5% who preferred being tested by a clinician. The findings came from a...
ASCO’s CancerLinQ® and Atropos Health Collaborate to Harness Real-World Data to Provide Point-of-Care Informatics Consult to Oncologists
ASCO’s CancerLinQ® and Atropos Health announced today a new collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.Atropos Health and CancerLinQ will work together to provide a...
Case Study Examines Differences Between AI and Radiologist Perception in Breast Cancer Screening
Radiologists and artificial intelligence (AI) systems yield significant differences in breast cancer screenings, a team of researchers has found. The case study by Makino et al, which appears in the journal Nature Scientific Reports, reveals the potential value of using both human and AI methods in ...
Study Finds Long-Term Increase in Cancer Risk After High Childhood BMI
Men who had a high body mass index (BMI) as children are at an elevated risk of obesity-related cancer later in life, even if their weight was normal in young adulthood, according to a new study from researchers at the University of Gothenburg, Sweden. Célind et al published their findings in the...
Cancer Screening Accessibility Among Native Americans
In a scientific e-poster presented during the 2022 American Roentgen Ray Society Annual Meeting in New Orleans, Peña et al noted that American Indian and Alaskan Native populations have nearly three times higher incidence rates of lung and colorectal cancer than other ethnic groups. These patterns...
Cancer Rates Declining in Canada, but Cases and Deaths Increasing Because of Demographic Factors
Overall cancer rates in Canada are declining, but the number of cases and deaths are increasing slightly because of population growth and an aging population, according to a new study published by Brenner et al in CMAJ (Canadian Medical Association Journal). The study is the result of a...
Patients With Cancer Face Greater Risks From Abdominal Aneurysm Repair
Elective abdominal aortic aneurysm repair in patients with a cancer diagnosis is associated with several poor postoperative outcomes, according to a newly published study from researchers at the University of Missouri School of Medicine. Roush et al reported their findings in the Journal of...
Study Identifies Genetic Changes in Patients With Barrett’s Esophagus That Progresses to Esophageal Cancer
Using whole-genome sequencing to contrast genomic alterations in patients with stable Barrett’s esophagus compared to patients whose Barrett’s progressed to esophageal adenocarcinoma, Paulson et al reported that DNA changes presaging esophageal cancer can be spotted years before cancer develops....
Increased Risk of Cancer in Early Life Among Individuals With Autism Spectrum Disorders
In the largest and most detailed population-based cohort study to date, researchers from the Karolinska Institute in Stockholm found that individuals with autism spectrum disorders, when present with comorbid intellectual disability and/or birth defects, were at a higher risk of cancer in early...
Gut Microbiome May Alter Response to Cancer Therapy
Recent findings with the use of sequencing technology have suggested that the gut microbiome may play a role in the treatment of cancer. A review paper published in JAMA Oncology by Liu and Shah captured the current understanding of the connection between the gut microbiome and therapeutic response ...
Study Finds CAR T-Cell Therapy Outcomes, Side Effects Are Similar in Black and Hispanic Patients Compared to White and Asian Patients
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and multiple myeloma. However, Black and Hispanic patients were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration...
Updated Guidance for COVID-19 Vaccination From NCCN Recommends Fifth mRNA Shot (Second Booster Dose) for Immunocompromised People
The National Comprehensive Cancer Network® (NCCN®) has released the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. The updated recommendations point to two booster vaccine doses for people who are immunocompromised (meaning three...
Matthew R. Smith, PhD, MD, on Prostate Cancer: Phase III Data on Darolutamide, Androgen Deprivation, and Docetaxel
Matthew R. Smith, PhD, MD, of Massachusetts General Hospital Cancer Center, discusses overall survival findings from the ARASENS trial, which assessed the efficacy of the androgen receptor inhibitor darolutamide vs placebo in combination with androgen-deprivation therapy and docetaxel for patients...
Priscilla K. Brastianos, MD, on CNS Metastases: Understanding Their Evolution and the Clinical Implications
Priscilla K. Brastianos, MD, of Harvard Medical School and Massachusetts General Hospital, talks about her efforts to better understand how brain metastases evolve genomically and to test such agents as abemaciclib, paxalisib, and entrectinib, which may stop their growth. Palbociclib, a CDK...
Timothy A. Yap, MBBS, PhD, on Ovarian, Breast, Pancreatic, and Prostate Cancers With Genetic Mutations: A First-in-Human Trial of AZD5305
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the PETRA study, a first-in-class, first-in-human trial of the next-generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2, or RAD51C/D mutations in advanced or metastatic...
Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses how research is building on the success of first-generation PARP inhibitors in the clinic and the potential of novel potent PARP1-selective inhibitors, which may lead to improved patient outcomes. Given...
Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response defects....
Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin
Gulam A. Manji, MD, PhD, of Columbia University Medical Center, discusses phase II results on perioperative combination chemotherapy and pembrolizumab in patients with resectable gastric cancer. The combination appeared to result in many complete pathologic responses (Abstract CT009).
Lillian L. Siu, MD, on Looking Toward the Future of Clinical Research and Clinical Trials
Lillian L. Siu, MD, of Canada’s Princess Margaret Cancer Centre, discusses biomarker-driven precision cancer medicine, the optimal sequencing of immunotherapy (IO) with standard treatments in curative settings, IO targets beyond PD-1/PD-L1 and combinatorial strategies, and next-generation adoptive...
Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment
Marcia R. Cruz-Correa, MD, PhD, of the University of Puerto Rico Comprehensive Cancer Center, discusses a way to possibly transform cancer outcomes by teaming up basic scientists, clinical researchers, and community advocates to work together, decode the complexity of cancer, and find points at...
Two Studies Examine Use of Proton-Beam Therapy in the United States
Two new, large studies led by researchers at the American Cancer Society showed an increase in the use of proton-beam therapy for patients with cancer in the United States during the past decade. However, Black patients were less likely to receive proton-beam therapy than White patients, and the...
New Study Examining Women’s Breast Density Knowledge Suggests Opportunities for Improvement
Breast density is one factor in assessing a person’s risk of developing breast cancer. Existing breast density notification laws have increased awareness among patients and providers, but clinical records had not been incorporated in studies to confirm the accuracy of personal breast density...
Study Examines Rates of Psychiatric Disorders and Self-Harm Among Patients Diagnosed Across 26 Cancer Types
The risk of self-harm after incident psychiatric disorder diagnosis in patients with 26 cancer types and the risk of unnatural deaths after self-harm were examined in 459,542 individuals in a study published by Chang et al in Nature Medicine. Patients with cancer may experience substantial...
AI May Assist Physicians in Better Assessing the Effectiveness of Bladder Cancer Treatment
In a small multi-institutional study, an artificial intelligence (AI)-based system improved providers’ assessments of whether patients with bladder cancer had complete response to chemotherapy before a radical cystectomy. These findings were published by Sun et al in Tomography. Yet the researchers ...
Erratum
In the article “OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer,” which began on page 1 of the April 10 issue of The ASCO Post, a few unfortunate errors appeared, notably an incorrect P value for the overall survival comparison (after...
Tony Hunter, PhD, FAACR, Honored With 2022 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) awarded the 2022 AACR Award for Lifetime Achievement in Cancer Research to Tony Hunter, PhD, FAACR, Fellow of the AACR Academy, at its Annual Meeting in New Orleans. Dr. Hunter is the American Cancer Society Professor and Renato Dulbecco Chair at ...
War in Ukraine: Statistics Do Not Keep Pace With Reality
Editor’s Note: The following is adapted from Dr. Hrynkiv’s presentation at the March 18 ASCO/ECO Briefing: Cancer Care During the War in Ukraine. Find resources for impacted patients and providers at asco.org/ukraine and onco-help.org. Official statistics regarding damage and losses in Ukraine are...
Philip D. Greenberg, MD, FAACR, Voted AACR President-Elect for 2022–2023
The members of the American Association for Cancer Research (AACR) have chosen Philip D. Greenberg, MD, FAACR, as the Association’s President-Elect for 2022–2023. Dr. Greenberg is the Rona Jaffe Foundation Endowed Chair and Professor and Head of the Program in Immunology, Clinical Research...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to...
Why Are Many Women Overdue for Cervical Cancer Screening?
Cervical cancer screening has reduced new cases and deaths from the disease over the past 50 years. However, the percentage of women in the United States who are overdue for cervical cancer screening has been growing, and the reasons have not been clear. To better understand the decline in cervical ...
Andrew Chapman, DO, FACP, Appointed Director of the Sidney Kimmel Cancer Center–Jefferson Health, Philadelphia
Andrew Chapman, DO, FACP, has been named Director of the Sidney Kimmel Cancer Center–Jefferson Health, with locations in Philadelphia and nearby areas in Pennsylvania and New Jersey. He has also been named the Center’s Executive Vice President for Oncology Services. He has served as the Center’s...
Fox Chase Cancer Center Appoints Elizabeth Plimack, MD, MS, as Deputy Director
Elizabeth Plimack, MD, MS, has been appointed to Deputy Director at Fox Chase Cancer Center in Philadelphia, according to Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase. Dr. Plimack is Chief of the Division of Genitourinary Medical Oncology and Professor in the Department of...
Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer. Researchers from Weill Cornell Medicine have found that while these ...
New Factors That Can Predict Breast Cancer Recurrence Identified
Genetics and other factors that can determine if a woman is at risk for a recurrence of breast cancer have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing new research avenues for preventing a new tumor from developing. The discovery was made possible...
Study Shows Medical Financial Hardship Increases Mortality Risk for Cancer Survivors
New findings from a large national study led by researchers at the American Cancer Society (ACS) show cancer survivors in the United States who reported medical financial hardship had a higher mortality risk than cancer survivors without financial hardship. Medical financial hardship was measured...
Virtual Panel Explores Impact of Racism on the Cancer Burden Facing Asian Americans
On July 21, 2021, the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA) convened a panel discussion entitled “Conversations on Cancer” to address the significant cancer disparities facing Asian Americans. The virtual “conversation” focused on the unfair burden impacting...
